SCHEMBL26127751

SCHEMBL26127751

C[C@H]1CNCC[C@@H]1NC(=O)C1(Cc2ccc(Cl)cc2)CC1

nearest known ligand 0.78

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ SSTR4 P31391 12/20 0.78
▸ SSTR1 P30872 9/20 0.78
▸ TDP1 Q9NUW8 1/20 0.38
▸ POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL30601817 0.93 SSTR4 (0.69) SSTR4SSTR1TDP1
SCHEMBL26122040 0.88 SSTR4 (0.69) SSTR4SSTR1
SCHEMBL30601806 0.88 SSTR4 (1.00) SSTR4SSTR1
SCHEMBL26127350 0.88 SSTR4 (1.00) SSTR4SSTR1
SCHEMBL26124582 0.86 SSTR4 (0.72) SSTR4SSTR1
Trifluoroacetic Acid SCHEMBL30601840 0.83 SSTR4 (0.62) SSTR4SSTR1
Trifluoroacetic Acid SCHEMBL30601822 0.82 SSTR4 (0.87) SSTR4SSTR1
Trifluoroacetic Acid SCHEMBL30601829 0.81 SSTR4 (0.64) SSTR4SSTR1
SCHEMBL26523249 0.80 SSTR4 (0.53) SSTR4SSTR1POLB
SCHEMBL26127403 0.80 SSTR4 (0.63) SSTR4SSTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188037-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES TAKEDA PHARMACEUTICALS CO (JP) 2025-06-12 — — US claimed
CN-119585238-A N- (pyrrolidin-3-yl or piperidin-4-yl) acetamide derivatives 武田药品工业株式会社 2025-03-07 — — CN claimed
EP-4499224-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES Takeda Pharmaceutical Company Limited (JP) 2025-02-05 — — EP claimed
WO-2023187677-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-05 — — WO claimed
US-20250188037-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES TAKEDA PHARMACEUTICALS CO (JP) 2025-06-12 — — US disclosed
CN-119585238-A N- (pyrrolidin-3-yl or piperidin-4-yl) acetamide derivatives 武田药品工业株式会社 2025-03-07 — — CN disclosed
EP-4499224-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES Takeda Pharmaceutical Company Limited (JP) 2025-02-05 — — EP disclosed
WO-2023187677-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-05 — — WO disclosed
WO-2023187677-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188037-A1 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES SSTR4, SSTR3, SSTR1 SSTR4 1/4885SSTR1 3/4885TDP1 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback